GLP-1R activation has a significanteffecton glycemic control in patients with T2DM through a variety ofmechanisms, including stimulation of insulin secretion, inhibition of glucagon secretion, protection of β-cells from apoptosis, slowing gastric emptying and increasing satiety (Drucker, 2006).
Sep 18, 2024Inrecent years,GLP-1medications have become a focal point in the medical community due to their innovative treatmentmechanisms, significant therapeutic efficacy, and broad development prospects.
May 1, 2025Recent cryo-electron microscopy and crystallographic studies, supported by functional analyses, revealed the intricate signal transductionmechanismsofGLP-1R and delineated distinct recognition patterns for both peptidic and small-molecule agonists.
Glucagon-like peptide-1 (GLP-1) has emerged as a gut-derived peptide with pleiotropic actions and has demonstrated therapeutic efficacy for cardiometabolic disorders, principally diabetes and obesity. Herein, Drucker provides an updated perspective on the physiological importance,mechanisms, and pathways underlying the efficacy and safety of nativeGLP-1andGLP-1R agonists.
Jul 11, 2025IntroductionGLP-1receptor agonists are a class ofantidiabeticdrugs that mimic the action of glucagon-like peptide-1 (GLP-1), an incretin hormone that enhances insulin secretion in response to meals. These agents are used primarily in the treatment of type 2 diabetes mellitus and obesity. Their unique ability to improve glycemic control without causing significant hypoglycemia, along with ...
Jul 25, 2025Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists represent a transformative class of therapeutic agents in the contemporary management of type 2 diabetes mellitus (T2DM) and chronic weight management. This extensive review meticulously explores the intricate physiological roles of endogenousGLP-1, delineates the sophisticatedmechanismsby which pharmacologicalGLP-1receptor ...
Glucagon-like peptide-1 (GLP-1) is an incretin peptide hormone mainly secreted by enteroendocrine intestinal L-cells.GLP-1is also secreted by α-cells of the pancreas and the central nervous system (CNS).GLP-1secretion is stimulated by nutrient intake and exerts itseffectson glucose homeostasis by stimulating insulin secretion, gastric emptying confiding the food intake, and β-cell ...
Jan 9, 2026TheGLP‑1mechanismofaction offers a multifaceted approach to managing type 2 diabetes, obesity, and potentially more. From itseffectson insulin and glucagon to appetite, cardiovascular protection, liver health, and even brain function,GLP‑1therapy represents one of the most transformative developments in endocrinology.
Jan 8, 2026INTRODUCTION Glucagon-like peptide1(GLP-1)-based therapies (eg,GLP-1receptor agonists, dual-actingGLP-1and glucose-dependent insulinotropic polypeptide [GIP] receptor agonists) affect glycemia through severalmechanisms, including increased glucose-dependent insulin secretion, slowed gastric emptying, and reduced food intake and postprandial glucagon secretion (table1). This topic will ...
Mar 14, 2026GLP-1exerts its therapeuticeffectsthrough multiplemechanisms: glucose-dependent insulin secretion from pancreatic β-cells, inhibition of glucagon release, delayed gastric emptying via vagal pathways, and central appetite suppression through hypothalamic and brainstem receptors.1
4 days agoTheantidiabeticagents function through variousmechanisms: Biguanides like Metformin reduce glucose production in the liver and enhance insulin sensitivity;GLP-1agonists stimulate insulin release and slow gastric emptying; SGLT2 inhibitors promote glucose excretion via the kidneys; DPP-4 inhibitors enhance incretin levels to increase insulin secretion; and Sulfonylureas stimulate insulin ...
Another class of anti-diabetes drugs, DPP-4 inhibitors, work by reducing the breakdown of endogenousGLP-1, and are generally considered less potent thanGLP-1agonists. [4] Some of the metaboliceffectsofGLP-1agonists in rodents are mediated via increased synthesis of fibroblast growth factor 21.
GLP-1receptor agonists, individually and as a group, were compared with non-use ofGLP-1receptor agonists and directly with other second-lineantidiabeticmedications. A within-individual design was used for all comparisons to reduce confounding, comparing periods of use versus periods of non-use of a medication in the same individual.
Apr 14, 2025Learn howGLP-1drugs work for diabetes and weight loss. ExploreGLP-1benefits, sideeffects, and emerging research on these medications.
3 days agoTable of Contents UnderstandingGLP-1Medications The Basics ofGLP-1Medications HowGLP-1Medications Function in the BodyMechanismsfor Blood Sugar and Appetite Control Role in Weight Management Pathways Insights from Recent Studies Practical Applications ofGLP-1Medications Getting Started and Daily Integration Managing Common SideEffectsBest Practices for Weight Loss Outcomes Advanced...
Mar 14, 2026GLP-1Pros and Cons: The Complete, Honest GuideGLP-1medications are the most effective weight loss drugs ever developed — and they carry real risks and real limitations that deserve honest examination. This is the complete, evidence-based breakdown of every advantage and disadvantage, grounded in clinical trial data rather than hype or fear.
Learn about the different classes of non-insulin type 2 diabetes medications used to lower blood glucose levels. Explore options like Metformin, DPP-4 inhibitors,GLP-1, and more.
2 days agoTheEffectofOralAntidiabeticDrugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis.
MechanismofActionGLP-1receptor agonists work through severalmechanisms: Stimulating insulin secretion: They prompt the pancreas to release insulin, but only when blood sugar levels are elevated, which means the risk of hypoglycemia (low blood sugar) is low.
Abstract Glucagon-like peptide-1 receptor (GLP-1R) is a critical therapeutic target for type 2 diabetes mellitus (T2DM). TheGLP-1R cellular signalingmechanismrelevant to insulin secretion and blood glucose regulation has been extensively studied. Numerous drugs targetingGLP-1R have entered clinical treatment. However, novel functional molecules with reduced sideeffectsand enhanced ...
Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular ...
Apr 2, 2024This review begins by a summary of the sources,anti-diabeticeffectsand the gut microbiota regulation functions of natural polysaccharides. Then, themechanismsofpolysaccharides in regulating the gut microbiota to exertanti-diabeticeffectsand the structure-activity relationship are summarized.
Research overview of mazdutide, a dual GLP-1/glucagon receptor agonist, coveringmechanisms, clinical trial data, pharmacokinetics, and regulatory status.
7 days agoTirzepatide's uniquemechanismofaction involves binding to theGLP-1receptor, mimicking the natural peptide and enhancing glucose-dependent insulin secretion. This results in improved glycemic control, reduced body weight, and increased feelings of fullness, ultimately making it an attractive treatment option for individuals with obesity or type 2 diabetes.
Jul 30, 2025Here, we report a neuralmechanismvia the small guanosine triphosphatase Ras- related protein1(Rap1). Mice with forebrain- specific Rap1 knockout exhibited resistance to theantidiabeticef-fectsoflow- dose metformin while remaining sensitive to otherantidiabeticagents.